Acc Releases Consensus Decision Pathway For Cvd Risk Reduction In T2d And Ascvd | Latest News RSS feed

Acc Releases Consensus Decision Pathway For Cvd Risk Reduction In T2d And Ascvd - Latest News


ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD

Examples of SGLT2 inhibitor drugs include empagliflozin and canagliflozin, both of which may reduce major adverse cardiac events (MACE) as well as heart failure hospitalization. The EMPA-REG OUTCOME ( ... read more

AHA: Rivaroxaban lowers brain bleed risk in A-fib

HealthDay News -- A once daily oral dose of rivaroxaban (Xarelto) significantly lowers the risk for intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) who are at moderate to high ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us